HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

imipenem drug combination cilastatin (Primaxin)

Subscribe to New Research on imipenem drug combination cilastatin

combination of imipenem and cilastatin

Also Known As:

Primaxin; cilastatin, imipenem drug combination; MK 0787-MK 0791 mixture; MK 787-MK 791 mixture; Merck Frosst brand of imipenem-cilastatin, sodium salt; Merck Sharp & Dohme brand of imipenem-cilastatin, sodium salt; Merck brand of imipenem-cilastatin, sodium salt; Thienam; Tienam 500; Zienam; imipenem - cilastatin; imipenem-cilastatin; imipenem-cilastatin, sodium salt

Networked: 582 relevant articles (112 outcomes, 159 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Kohno, Shigeru: 4 articles (07/2013 - 01/2002)
2.	Kuti, Joseph L: 4 articles (02/2008 - 01/2005)
3.	Nicolau, David P: 4 articles (02/2008 - 01/2005)
4.	Dartois, Nathalie: 3 articles (04/2013 - 09/2005)
5.	Babinchak, Timothy: 3 articles (01/2010 - 01/2005)
6.	Cooper, Angel: 3 articles (01/2010 - 09/2006)
7.	Wu, Shu-Chen: 3 articles (05/2006 - 02/2003)
8.	Susic, Veselinka: 3 articles (04/2004 - 02/2004)
9.	Zivanovic, Dragana: 3 articles (04/2004 - 02/2004)
10.	Okuno, Yuji: 2 articles (04/2015 - 06/2013)

Related Diseases

1.	Infection 02/01/1988 - "Imipenem/cilastatin is highly effective for infections in many body sites against a broad range of gram-positive and gram-negative aerobic and anaerobic bacteria. " 06/07/1985 - "Preliminary data indicate that imipenem/cilastatin is very effective in the therapy of this serious infection; however its place in the therapeutic armamentarium awaits the completion of randomized prospective studies against established drugs." 12/01/1986 - "In this study imipenem/cilastatin was used successfully to treat 21 patients with a variety of severe infections caused by Gram-positive and Gram-negative aerobic bacteria. " 01/01/1991 - "The efficacy and low incidence of side effects of the intramuscular formulation of imipenem/cilastatin are significant advantages in the cost-effective treatment of infections." 01/01/1988 - "Imipenem-cilastatin appears to be an effective antibiotic in treating polymicrobial infections; however, a much larger patient population would be required to detect a significant difference in the efficacy rates or frequency of adverse effects when comparing the two regimens."
2.	Pneumonia (Pneumonitis) 06/01/2014 - "Imipenem/cilastatin therapy was found to be effective for the treatment of Legionella pneumonia in this patient." 02/01/1985 - "Results of this study suggest that primaxin will be useful in the treatment of a variety of serious Gram-positive and Gram-negative pneumonias. " 06/01/2006 - "The efficacy and safety of P/T was compared with imipenem/cilastatin (I/C) in patients with established nosocomial pneumonia. " 12/01/2004 - "One week later, the patient developed pneumonia, and imipenem/cilastatin was added. " 04/01/2003 - "Rapid imipenem/cilastatin desensitization for multidrug-resistant Acinetobacter pneumonia."
3.	Urinary Tract Infections (Urinary Tract Infection) 06/07/1985 - "Safety and efficacy of imipenem/cilastatin in treatment of complicated urinary tract infections." 01/01/2015 - "Another phase II clinical trial has demonstrated that clinical cure rates with CAZ/AVI are comparable to those with imipenem/cilastatin for the treatment of adults with complicated urinary tract infections (cUTIs). " 01/01/1992 - "To determine the cost relative to efficacy and tolerability of two antimicrobial regimens, a prospective, multicenter study compared imipenem-cilastatin (I-C) monotherapy with clindamycin+aminoglycoside (C+A) in the treatment of serious lower respiratory, intra-abdominal, gynecologic, and urinary tract infections. " 01/01/1992 - "Cost-analysis of imipenem-cilastatin monotherapy compared with clindamycin+aminoglycoside combination therapy for treatment of serious lower respiratory, intra-abdominal, gynecologic, and urinary tract infections." 01/01/1986 - "A total of 20 urological patients suffering from complicated urinary tract infections (15 men, five women) received a short-term i.v. infusion of 0.5 mg imipenem/cilastatin t.i.d. "
4.	Sepsis (Septicemia) 10/01/2000 - "After sepsis treatment with imipenem-cilastatin and aminoglycoside, remission of hemophagocytosis was achieved." 01/01/1987 - "The clinical efficacy and safety of imipenem/cilastatin in the empirical treatment of adult non-immunocompromised patients with severe bacterial septicemia was studied in a prospective and open trial. " 01/01/1995 - "The effects of experimental splenic autotransplantation and imipenem-cilastatin treatment in postsplenectomy Pseudomonas aeruginosa sepsis." 05/31/1989 - "[Monotherapy, empirical and targetted, with imipenem-cilastatin in sepsis of bacterial origin]." 07/25/1988 - "One patient in the imipenem/cilastatin arm died of Pseudomonas aeruginosa sepsis. "
5.	Respiratory Tract Infections (Respiratory Tract Infection) 06/07/1985 - "Monotherapy with imipenem/cilastatin of serious lower respiratory tract infections was relatively safe and highly effective with the exception of disease associated with P. " 01/01/1988 - "Imipenem-cilastatin in the treatment of respiratory infections in patients with chronic airways obstruction." 12/01/1986 - "Six patients, aged between 68 and 83 years, with glomerular filtration rates (GFR) between 31 and 80 ml/min received imipenem/cilastatin as treatment for acute lower respiratory tract infection. " 07/01/1985 - "Imipenem/cilastatin compares well with the most active agents available for therapy for lower respiratory tract infections." 07/01/1985 - "Therapy for lower respiratory tract infections with imipenem/cilastatin: a review of worldwide experience."

Related Drugs and Biologics

1.	meropenem (Merrem)
2.	Sodium
3.	Clindamycin (Cleocin)
4.	Ceftazidime (Fortum)
5.	Vancomycin
6.	Ciprofloxacin (Cipro)
7.	Imipenem
8.	Metronidazole (Metric)
9.	Piperacillin
10.	tazobactam

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Continuous Ambulatory Peritoneal Dialysis (CAPD)
3.	Combination Drug Therapy (Combination Chemotherapy)
4.	Stem Cell Transplantation
5.	Renal Dialysis (Hemodialysis)